Nicox attends 2013 congress of the French Society of Ophthalmology (SFO) in Paris


Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX) is attending for the first time the 119th congress of the French Society of Ophthalmology (SFO) taking place from May 11 to 14, 2013 in Paris, France. Nicox can be found at booth number N14.

Nicox’s European and International Operations team, including Philippe Masquida, Vice President and Managing Director of European and International Operations of Nicox Pharma will present AdenoPlus®, a rapid point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis.

About Nicox

Nicox (Bloomberg: COX-FP, Reuters: NCOX.PA) is creating a new mid-sized international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools. With a heritage of scientific, business development and commercial expertise, the Nicox team is focused on developing and marketing novel pharmaceuticals and diagnostic devices that can help people to enhance their sight. In the United States, Nicox markets AdenoPlus®, a test for the differential diagnosis of acute conjunctivitis inlicensed from RPS®.

The Company’s pipeline includes latanoprostene bunod, a novel drug-candidate based on Nicox’s proprietary nitric oxide (NO)-donating R&D platform, developed in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donating compounds are under development in nonophthalmic indications, notably through partners, including Merck (known as MSD outside the United States and Canada).

Nicox S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: SmallCaps). For more information please visit www.nicox.com.
This communication may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on March 22, 2013 and available on Nicox’s website (www.nicox.com) and on the AMF’s website (www.amf-france.org).